Jump Financial LLC lowered its position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 51.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,353 shares of the company's stock after selling 3,490 shares during the period. Jump Financial LLC's holdings in AstraZeneca were worth $246,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Goldman Sachs Group Inc. boosted its stake in shares of AstraZeneca by 30.9% during the first quarter. Goldman Sachs Group Inc. now owns 13,647,948 shares of the company's stock valued at $1,003,124,000 after purchasing an additional 3,224,251 shares during the period. American Century Companies Inc. increased its holdings in shares of AstraZeneca by 406.9% in the first quarter. American Century Companies Inc. now owns 2,020,629 shares of the company's stock valued at $148,517,000 after purchasing an additional 1,621,974 shares during the period. Boston Partners boosted its stake in shares of AstraZeneca by 35.9% during the first quarter. Boston Partners now owns 5,036,645 shares of the company's stock valued at $368,712,000 after acquiring an additional 1,329,166 shares during the last quarter. Point72 Asset Management L.P. raised its holdings in shares of AstraZeneca by 815.8% during the 4th quarter. Point72 Asset Management L.P. now owns 1,073,630 shares of the company's stock valued at $70,344,000 after buying an additional 1,223,630 shares during the period. Finally, Deutsche Bank AG raised its stake in shares of AstraZeneca by 650.1% in the 1st quarter. Deutsche Bank AG now owns 1,234,847 shares of the company's stock worth $90,761,000 after buying an additional 1,070,223 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company's stock.
AstraZeneca Trading Down 0.5%
Shares of AstraZeneca stock traded down $0.44 during mid-day trading on Monday, hitting $81.26. The stock had a trading volume of 1,292,975 shares, compared to its average volume of 5,150,503. AstraZeneca PLC has a 12-month low of $61.24 and a 12-month high of $83.43. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.55. The firm has a market cap of $252.01 billion, a P/E ratio of 30.52, a price-to-earnings-growth ratio of 1.50 and a beta of 0.37. The firm has a 50-day moving average of $74.90 and a two-hundred day moving average of $72.73.
AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $1.09 earnings per share for the quarter, meeting analysts' consensus estimates of $1.09. The business had revenue of $14.46 billion during the quarter, compared to analyst estimates of $14.08 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The company's revenue was up 16.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.24 earnings per share. Sell-side analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current year.
AstraZeneca Cuts Dividend
The company also recently disclosed a semi-annual dividend, which will be paid on Monday, September 8th. Shareholders of record on Friday, August 8th will be issued a dividend of $0.505 per share. This represents a yield of 200.0%. The ex-dividend date of this dividend is Friday, August 8th. AstraZeneca's payout ratio is currently 37.97%.
Analyst Upgrades and Downgrades
Separately, Berenberg Bank set a $97.00 target price on AstraZeneca in a research report on Wednesday, July 9th. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $86.00.
Read Our Latest Stock Analysis on AZN
AstraZeneca Company Profile
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Further Reading
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
